Claim0556f2435074361146313cba4fa7ed59c0e6fed007017137283abfbaf18e543a·My Arguments

Claim

In the SELECT randomized controlled trial — 17,604 adults with obesity and established cardiovascular disease but no diabetes, followed for a mean of ~40 months — once-weekly semaglutide reduced major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) by 20% versus placebo, with concordant reductions in renal outcomes and progression to diabetes.

Evidence (1)

SELECT trial summary
20% MACE reduction over ~40 months in 17,604 non-diabetic adults with obesity and established CVD.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/0556f2435074361146313cba4fa7ed59c0e6fed007017137283abfbaf18e543a"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberationJoin & respond